摘要
目的探讨沙库巴曲缬沙坦(S/V)对植入埋藏式心律转复除颤器(ICD)进行心脏性猝死(SCD)一级预防的射血分数下降性的慢性心力衰竭(HFrEF)患者心功能及室性心律失常的影响。方法纳入2017年9月至2022年12月期间在云南省第一人民医院心血管内科住院的接受S/V治疗并植入ICD进行SCD一级预防的HFrEF患者。(1)统计患者随访12个月时S/V剂量,治疗3月、6月、12月时心脏彩超指标(LVEF、LVEDD、LAD);(2)ICD记录的室性心律失常事件及治疗情况,动态心电图指标:平均每小时室性早搏次数、全部窦性心搏RR间期的标准差(SDNN)及校正后的平均QT间期(QTc)。结果共纳入56例患者。(1)随访1 a时,S/V的平均用药剂量为94.6 mg,bid。(2)随访3月LVEF、LVEDD、LAD均较治疗前改善;随访6月LVEF、LVEDD、LAD较治疗3月时改善;随访12月LVEF、LVEDD、LAD较治疗6月时改善,差异均有统计学意义(P<0.05)。(3)与随访1~6月相比较,随访7~12月患者室性心动过速/心室颤动(VT/VF)、非持续性室性心动过速(NSVT)、监测室速发作次数均减少,差异有统计学意义(P<0.05)。(4)与治疗前相比较,随访1 a患者SDNN由(94.38±26.42)ms增加至(102.23±20.36)ms;平均QTc由(441.92±10.64)ms缩短到(411.46±6.00)ms,差异均有统计学意义(P<0.05)。结论(1)植入ICD进行SCD一级预防的HFrEF患者服用S/V治疗的1 a内心脏结构及功能持续改善;(2)随访期间S/V减少了室性心律失常的发生。
Objectives To investigate the effects of sacubitril/valsartan(S/V)on cardiac function and ventricular arrhythmias in patients with chronic heart failure with reduced ejection fraction(HFrEF)who underwent primary prevention of sudden cardiac death(SCD)after implantation of an implantable cardioverter defibrillator(ICD).Methods HFrEF patients who were hospitalized in the Cardiovascular Department of the First People’s Hospital of Yunnan Province from September 2017 to December 2022 and received S/V treatment and ICD implantation for primary prevention of SCD were included.①We calculated the S/V dose of patients at 12 months of follow-up,as well as cardiac ultrasound indicators(LVEF,LVEDD,LAD)at 3,6,and 12 months of treatment;②ICD was used to record ventricular arrhythmia events and treatment status,dynamic electro-cardiogram indicators:average number of ventricular premature beats per hour,standard deviation(SDNN)of all sinus rhythm RR intervals,and corrected average QT interval(QTc).Results A total of 56 patients were included.(1)At oneyear follow-up,the average medication dose for S/V in all patients was 94.6 mg bid.(2)Following up for 3 months,LVEF,LVEDD,and LAD improved compared to before treatment(P<0.05);LVEF,LVEDD,and LAD improved after 6 months of follow-up compared to 3 months of treatment(P<0.05);LVEF,LVEDD,and LAD improved after 12 months of follow-up compared to 6 months of treatment(P<0.05).(3)Compared with 1-6 months of follow-up,the incidence of VT/VF,NSVT and monitored ventricular brachytherapy decreased during 7-12 months of follow-up(P<0.05).(4)Compared with before treatment,SDNN increased from(94.38±26.42)ms to(102.23±20.36)ms and average QTc decreased from(441.92±10.64)ms to(411.46±6.00)ms during 1-year follow-up(P<0.05).Conclusions(1)For HFrEF patients implanted with ICD for primary prevention of SCD,their cardiac structure and function was continued to improve within one year of receiving S/V treatment;(2)S/V reduced the occurrence of ventricular arrhythmias during the follow-up peri
作者
尚蒙
高晓龙
匡晓晖
张曦
张进
王礼琳
SHANG Meng;GAO Xiaolong;KUANG Xiaohui;ZHANG Xi;ZHANG Jin;WANG Lilin(Dept.of Cardiology,The Affiliated Hospital of Kunming University of Science and Technology/The 1st People’s Hospital of Yunnan Province,Kunming Yunnan 650032,China)
出处
《昆明医科大学学报》
CAS
2023年第11期63-69,共7页
Journal of Kunming Medical University
基金
国家自然科学基金资助项目(81360039)。
关键词
慢性心力衰竭
埋藏式心律转复除颤器
沙库巴曲缬沙坦
心功能
室性心律失常
Chronic Heart failure
Implantable cardioverter defibrillator
Sacubitril/Valsartan
Cardiac function
Ventricular arrhythmia
